In:
Blood, American Society of Hematology, Vol. 140, No. 2 ( 2022-07-14), p. 156-160
Kurzfassung:
Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral response to mRNA-based vaccines, patients demonstrate normal or heightened functional T-cell responses, including antiviral T-cell activity against SARS-CoV-2 variants including Omicron. Collectively, these data reinforce the importance of COVID-19 vaccination following CD19 CAR T-cell therapy, despite long-term B-cell aplasia.
Materialart:
Online-Ressource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood.2022016166
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2022
ZDB Id:
1468538-3
ZDB Id:
80069-7
